Medtronic: Modest Fourth Qtr. Growth Spurred by Resolute Integrity Launch
Medtronic’s fiscal 2012 earnings call brought both good news and bad. On the positive side of the ledger, the U.S. launch of the Resolute Integrity drug-eluting stent propelled the company to $80 million in domestic DES sales for the fourth quarter — doubling its market share and growing the product line’s revenue by 57 percent.
This article is viewable by subscribers only. To view this article, please select an option below.